Clinical trials: Alzheimer; Early Onset
Alzheimer Disease, Early Onset
Novel Dementia Biomarkers
The study will investigate structural and functional characteristics of the brain of dementia patients compared to healthy controls in order to get a better insight into importance of early biomarkers for the diagnosis of…
- Trial name
- NCT04427436
- Testing
- No Intervention
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)
Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown.
- Trial name
- NCT00987090
- Testing
- Clinic and neuropsychologic evaluation, MRI, PET
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset
Digital Evaluations and Technologies Enabling Clinical Translation for AD
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's disease.
- Trial name
- DETECT-AD (NCT05385913)
- Testing
- Multivitamin-no intervention
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Oregon Health and Science University
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Alzheimer Disease, Early Onset, Lewy Body Disease
Patients With Alzheimer's Disease or Related Youth Disease
This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.
- Conditions
- Alzheimer Disease, Early Onset, Lewy Body Disease, Frontotemporal Lobar Degeneration
- Trial name
- PARMAAJJ (NCT03508024)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Lille
Alzheimer Disease, Early Onset
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
- Trial name
- TargetTau-1 (NCT06268886)
- Testing
- BMS-986446
- Where
- 176 sites in United States, Australia and 8 more
- Volunteers
- 310 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Early Onset
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a…
- Trial name
- ROAD (NCT03625401)
- Testing
- AD-35 60mg group
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimer Disease, Alzheimer Disease, Early Onset
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies.
- Trial name
- TMSLA (NCT07036328)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Willem de Haan
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT05269394)
- Testing
- E2814, Lecanemab
- Where
- 36 sites in United States, Argentina and 14 more
- Volunteers
- 197 people
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset, Dementia
Cholinergic Deep Brain Stimulation for Alzheimer's Disease
This project will investigate the potential of Deep Brain Stimulation to improve cognitive abilities and counteract the effects of Alzheimer's disease.
- Conditions
- Alzheimer Disease, Early Onset, Dementia, Alzheimer Disease
- Trial name
- NCT05882344
- Testing
- Device Implantation- Boston Scientific, VERCISE GENUS™ system, DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease, Alzheimer Disease, Early Onset
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes)
- Trial name
- NCT05655195
- Testing
- GENUS device (Active Settings)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
Alzheimer Disease, Early Onset
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease.
- Trial name
- LITES (NCT05573490)
- Testing
- Cognitive Training, Tai Chi- Qi Gong, Brain Games
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Alzheimer's Disease, Dementia
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of…
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Trial name
- DIAN-TU (NCT06384573)
- Testing
- lecanemab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau…
- Trial name
- SToMP-AD (NCT04685590)
- Testing
- Dasatinib + Quercetin
- Where
- 5 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset Alzheimer Disease
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild…
- Trial name
- NCT03634007
- Testing
- LX1001
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lexeo Therapeutics